✨ Entering our GLP-1 Agonist Era ✨

✨ Entering our GLP-1 Agonist Era ✨

Dr. Martha Gulati as she breaks down how GLP-1 receptor agonists are changing preventive cardiology, and what’s next.

She discusses the STRIDE study, which showed that GLP-1s improve outcomes in patients with overweight or obesity, even without diabetes.

And new data on high-dose oral semaglutide found a significant reduction in major cardiovascular events among patients with established ASCVD.

🎙️ Moderated by interventionalist Dr. Priya Kothapalli, this conversation breaks down what every cardiologist should know entering our GLP-1 agonist era, as well as breaking down the cardiology specialty silos, how the cardiology community has grown stronger and more connected, and more!

.
Sources:
.
.
.
.
#Cardiology #glp1 #medicalresearch #preventivecardiology #stridestudy #semaglutide #ASCVD #HeartHealth #medicaleducation #ACC25 #PeripheralArteryDisease #ObesityCare #CardiologyEducation